American Society of Hirudotherapy

Design of potent bivalent thrombin inhibitors based on hirudin sequence: incorporation of nonsubstrate-type active site inhibitors

Research article published in Biochemistry (1994)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportDrug DevelopmentSalivary PharmacologyTsuda Y et al. · Biochemistry, 1994

Abstract

Hirudin from medicinal leech is the most potent and specific thrombin inhibitor from medicinal leech with a K(i) value of 2.2 x 10(-14) M. It consists of an active site blocking moiety, hirudin1-48, a fibrinogen-recognition exo-site binding moiety, hirudin55-65, and a linker, hirudin49-54, connecting these inhibitor moieties. Synthetic inhibitors were designed based on the C-terminal portion of hirudin. The bulky active site blocking moiety, hirudin1-48, was replaced by small nonsubstrate-type active site inhibitors of thrombin, e.g., dansyl-Arg-(D-pipecolic acid). The linker moiety was replaced by omega-amino acids of (12-aminododecanoic acid)-(4-aminobutyric acid), and hirudin55-65 was used as a fibrinogen-recognition exo-site binding moiety in most of the inhibitors. The crystal structure of the inhibitor in complex with human alpha-thrombin showed that dansyl, Arg, and D-pipecolic acid of the active site blocking moiety occupy S3, S1, and S2 subsites of thrombin, respectively, and were therefore designated as P3, P1, and P2 residues. The use of dansyl-Arg-(D-pipecolic acid) improved the affinity (K(i)) of the inhibitor 10-100-fold (down to 1.70 x 10(-11) M) compared to that of the similar compounds having D-Phe-Pro-Arg as their substrate-type inhibitor moiety (K(i) = 10(-9)-10(-10) M). The linker connected to P2 residue eliminated the scissile peptide bond. The inhibitor was also stable against human plasma proteases. Further inhibitor design revealed that the toxic dansyl group could be replaced by 4-tert-butylbenzenesulfonyl group and 1- or 2-naphthalenesulfonyl group for in vivo studies.(ABSTRACT TRUNCATED AT 250 WORDS)

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAmino Acid SequenceAnimalsBinding SitesCrystallography, X-RayDrug DesignEndopeptidasesHirudinsHumansIn Vitro TechniquesKidneyKineticsModels, MolecularMolecular Sequence DataPeptidesProtein Structure, TertiaryRatsRats, Sprague-DawleyStructure-Activity RelationshipThrombin

Summary

Replacing hirudin's bulky active-site-blocking segment with dansyl-Arg-(D-pipecolic acid), while keeping the hirudin55-65 exosite-binding tail, yielded bivalent thrombin inhibitors with Ki down to 1.70 x 10(-11) M, stable against human plasma proteases.

Why This Matters for Hirudotherapy

This study describes the rational design of bivalent thrombin inhibitors modeled on hirudin—the most potent and specific thrombin inhibitor from the medicinal leech (Ki = 2.2 × 10⁻¹⁴ M)—by replacing the bulky active-site blocking moiety (hirudin1-48) with smaller nonsubstrate-type inhibitors and retaining the C-terminal exosite-binding fragment (hirudin55-65). Crystallographic analysis confirmed that the synthetic inhibitors occupied thrombin's S1, S2, and S3 subsites, achieving Ki values down to 1.70 × 10⁻¹¹ M, with improved plasma protease stability and identification of less toxic group replacements for potential in vivo studies. The study is purely in vitro with no leeches or hirudotherapy involved.

Citation

Reference (Vancouver style)

Tsuda Y, Cygler M, Gibbs BF, Pedyczak A, Féthière J, Yue SY, et al. Design of potent bivalent thrombin inhibitors based on hirudin sequence: incorporation of nonsubstrate-type active site inhibitors. Biochemistry. 1994;33(48):14443-14451. doi:10.1021/bi00252a010. PMID: 7981204

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.